Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Jihyun | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Han, Jae-joon | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Lee, Jeong-Ok | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Choi, Yoon-seok | - |
dc.contributor.author | Kim, Sung hyun | - |
dc.contributor.author | Yoon, Sung-soo | - |
dc.date.available | 2020-02-27T20:41:30Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 2045-7634 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6577 | - |
dc.description.abstract | We analyzed the treatment responses, toxicities, and survival outcomes of patients with relapsed or refractory multiple myeloma who received daily thalidomide, cyclophosphamide, and dexamethasone (CTD) or daily thalidomide, melphalan, and prednisolone (MTP) at 17 medical centers in Korea. Three-hundred and seventy-six patients were enrolled. The combined chemotherapy of thalidomide, corticosteroid, and an alkylating agent (TAS) was second-line chemotherapy in 142 (37.8%) patients, and third-line chemotherapy in 135 (35.9%) patients. The response rate overall was 69.4%. Patients who were not treated with bortezomib and lenalidomide before TAS showed a higher response rate compared to those who were exposed to these agents. The estimated median progression-free survival and overall survival times were 10.4months and 28.0months, respectively. The adverse events during TAS were generally tolerable, but 39 (10.4%) patients experienced severe infectious complications. There were no differences in terms of efficacy between CTD and MTP, but infectious complications were more common in CTD group. TAS is an effective treatment regimen which induces a high response rate in relapsed or refractory multiple myeloma patients. Due to the high incidence of grade 3 or 4 infection, proper management of infection is necessary during the TAS treatment, especially the CTD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.subject | LOW-DOSE THALIDOMIDE | - |
dc.subject | PLUS DEXAMETHASONE | - |
dc.subject | INDUCTION THERAPY | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | SALVAGE THERAPY | - |
dc.subject | INITIAL THERAPY | - |
dc.subject | PHASE-II | - |
dc.subject | CYCLOPHOSPHAMIDE | - |
dc.subject | PREDNISONE | - |
dc.subject | MELPHALAN | - |
dc.title | Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000393865900010 | - |
dc.identifier.doi | 10.1002/cam4.970 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, v.6, no.1, pp.100 - 108 | - |
dc.identifier.scopusid | 2-s2.0-85006141588 | - |
dc.citation.endPage | 108 | - |
dc.citation.startPage | 100 | - |
dc.citation.title | CANCER MEDICINE | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Alkylating agent | - |
dc.subject.keywordAuthor | cyclophosphamide | - |
dc.subject.keywordAuthor | melphalan | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | thalidomide | - |
dc.subject.keywordPlus | LOW-DOSE THALIDOMIDE | - |
dc.subject.keywordPlus | PLUS DEXAMETHASONE | - |
dc.subject.keywordPlus | INDUCTION THERAPY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | SALVAGE THERAPY | - |
dc.subject.keywordPlus | INITIAL THERAPY | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | PREDNISONE | - |
dc.subject.keywordPlus | MELPHALAN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.